Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

SK Biopharmaceuticals   / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sk-biopharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:28966:1" rel="noopener">SK Biopharmaceuticals Co Ltd (326030 KS)</a> has two marketed drugs for central nervous system disorders. Last year, the company launched its independently developed drug Xcopri (cenobamate) in the U.S.</li>
<li>The company has initiated phase 3 clinical trial for Xcopri in Asia in sync with its objective to expand beyond the U.S. and to enhance presence in Asia.</li>
<li>SK Biopharmaceuticals entered into greater China and acquired a 45% stake in Ignis Therapeutics through out-licensing six of its clinical pipelines.</li>
</ul>



SK Biopharmaceuticals Co Ltd (326030 KS) has two marketed drugs for central nervous system disorders. Last year, the company launched its independently developed drug Xcopri (cenobamate) in the U.S.
The company has initiated phase 3 clinical trial for Xcopri in Asia in sync with its objective to expand beyond the U.S. and to enhance presence in Asia.
SK Biopharmaceuticals entered into greater China and acquired a 45% stake in Ignis Therapeutics through out-licensing six of its clinical pipelines.


SK Biopharmaceuticals (326030 KS): A Promising Play on Central Nervous System Disorders

Takeda’s stock plunged 12% in last one year to trade near its 52-week low. On October 6, the company halted two phase 2 clinical trials of TAK-994 after safety signal emerged in the trials. Although it is still not clear whether TAK-994 will be discontinued, Takeda’s share price declined ~11% following the news. With forthcoming patent expiry of some key drugs, this setback on a heavyweight neuroscience pipeline leads to a jittery outlook for the company, at least in near-term. TAK-994 has the potential to become a blockbuster drug for the company, if approved. Takeda’s top selling gastroenterology drug Entyvio (2020 revenue ¥429 billion) is patent protected through May 2026, while its neuroscience drug Vyvanse’s (2020 revenue ¥272 billion) patent will expire in February 2023 in the U.S. Both the drugs report mid to high-teen percentage growth in revenue. The current pipeline lacks multiple late-stage candidates, which are likely to compensate for the patent cliff to be faced by Takeda.

Takeda’s stock plunged 12% in last one year to trade near its 52-week low. On October 6, the company halted two phase 2 clinical trials of TAK-994 after safety signal emerged in the trials. Although it is still not clear whether TAK-994 will be discontinued, Takeda’s share price declined ~11% following the news. With forthcoming patent expiry of some key drugs, this setback on a heavyweight neuroscience pipeline leads to a jittery outlook for the company, at least in near-term. TAK-994 has the potential to become a blockbuster drug for the company, if approved. Takeda’s top selling gastroenterology drug Entyvio (2020 revenue ¥429 billion) is patent protected through May 2026, while its neuroscience drug Vyvanse’s (2020 revenue ¥272 billion) patent will expire in February 2023 in the U.S. Both the drugs report mid to high-teen percentage growth in revenue. The current pipeline lacks multiple late-stage candidates, which are likely to compensate for the patent cliff to be faced by Takeda.    

Takeda Pharmaceutical (4502 JP): Recent Pipeline Blues Puts a Brake on Stock Recovery

Making sense of the Global Market, Euromonitor International Ltd.

Yu Mitsuhashi

Making sense of the Global Market

Euromonitor International Ltd.

We are a global market research company focused on industries, countries, economies and consumers worldwide. Our cross-country comparable research helps your organisation identify opportunities and develop growth strategies in countries and regions across the globe. With offices around the world, 1,200 analysts in 100 countries and market research on every key trend and driver, we give you powerful access to the real story behind consumer change.

Thematic (Sector/Industry)

While the US consumer health industry will remain a strong centre for investment, development and technology innovation in 2017 and is expected to reach US$77 billion by 2021, the election of Donald Trump has created uncertainty among the industry, government agencies and consumers, especially around regulations, local production incentives, and changes to the Affordable Care Act.

While the US consumer health industry will remain a strong centre for investment, development and technology innovation in 2017 and is expected to reach US$77 billion by 2021, the election of Donald Trump has created uncertainty among the industry, government agencies and consumers, especially around regulations, local production incentives, and changes to the Affordable Care Act.

Trump Health Effect: What Is Next for the Consumer Health Industry Under Trump's Leadership?

Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

<a href="https://www.smartkarma.com/entities/17686" target="_blank" data-smartkarma-citation="entities:17686:1">Ziopharm Oncology Inc (ZIOP US)</a> announced impressive survival data for its immune-boosting therapy AD-RTS-hIL-12 + veledimex in recurrent pediatric malignant glioma (a form of deadly brain cancer). Median overall survival almost doubled to 12.8 months vs. currently available therapies. In addition, any toxic effects were reversible on stopping veledimex (which thus acts as a control switch for the therapy). Griffin Securities reissued buy rating with price target of US$21 after the data was…

Ziopharm Oncology Inc (ZIOP US) announced impressive survival data for its immune-boosting therapy AD-RTS-hIL-12 + veledimex in recurrent pediatric malignant glioma (a form of deadly brain cancer). Median overall survival almost doubled to 12.8 months vs. currently available therapies. In addition, any toxic effects were reversible on stopping veledimex (which thus acts as a control switch for the therapy). Griffin Securities reissued buy rating with price target of US$21 after the data was…

Actionable Ideas in the Biotechnology and Pharmaceutical Sectors (Incl. Insider Buying): November 28

Among one of his first initiatives, U.S. President-elect Trump posted a preliminary plan to repeal the Affordable Care Act (ACA) on his transition team website, greatagain.gov. According to a post on this website: <blockquote>It is clear to any objective observer that the ACA, which has resulted in rapidly rising premiums and deductibles, narrow networks, and health insurance, has not been a success.</blockquote>According to this post, the Trump administration plans to do the following:<blockquote><ul><li>Work with Congress to allow…</li></ul></blockquote>

Among one of his first initiatives, U.S. President-elect Trump posted a preliminary plan to repeal the Affordable Care Act (ACA) on his transition team website, greatagain.gov. According to a post on this website: It is clear to any objective observer that the ACA, which has resulted in rapidly rising premiums and deductibles, narrow networks, and health insurance, has not been a success.According to this post, the Trump administration plans to do the following:Work with Congress to allow…

Just In: Trump's Preliminary Plan to Repeal the Affordable Care Act

Ireland

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Jazz Pharmaceuticals (JAZZ US)

SK Biopharmaceuticals (326030 KS): A Promising Play on Central Nervous System Disorders

SKBP's independently developed and marketed drug Xcopri has the potential to reach peak revenue of $1.5 billion in 2027. The company targets to...

Tina Banerjee

Takeda Pharmaceutical (4502 JP): Recent Pipeline Blues Puts a Brake on Stock Recovery

Takeda's shares are trading near 52-week low. Recent pipeline setback makes the near-term outlook jittery for the company.

Tina Banerjee

Trump Health Effect: What Is Next for the Consumer Health Industry Under Trump's Leadership?

While the US consumer health industry will remain a strong centre for investment, development and technology innovation in 2017 and is expected to...

Euromonitor International Ltd.

Actionable Ideas in the Biotechnology and Pharmaceutical Sectors (Incl. Insider Buying): November 28

Ziopharm Oncology Inc (ZIOP US) announced impressive survival data for its immune-boosting therapy AD-RTS-hIL-12 + veledimex in recurrent pediatric...

Dr. Bhavneesh Sharma, MD, MBA

Just In: Trump's Preliminary Plan to Repeal the Affordable Care Act

Among one of his first initiatives, U.S. President-elect Trump posted a preliminary plan to repeal the Affordable Care Act (ACA) on his transition...

Dr. Bhavneesh Sharma, MD, MBA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)